ArticleBMC pregnancy and childbirth2025
Associations of maternal serum transthyretin concentration with pregnancy and birth outcomes.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aims to explore the association of maternal serum transthyretin (TTR) concentrations with adverse pregnancy and birth outcomes, as well as the variations in TTR concentrations across different gestational weeks in relation to these outcomes.
methodsThis retrospective cohort study included 6,584 women who delivered at The Second Affiliated Hospital of Wenzhou Medical University between January 1, 2022 and January 30, 2024. Logistic regression and Restricted cubic spline (RCS) models were applied to evaluate the association between TTR levels and the risk of complications, based on TTR quartile analyses. Locally estimated scatter plot smoothing (LOESS) curves were performed to provide a graphical representation of the relationship between TTR levels and gestational weeks.
resultsSignificant negative correlations were observed between maternal TTR levels and the risk of gestational diabetes mellitus (GDM), preeclampsia (PE), liver disease, anemia during pregnancy, and preterm delivery (all P < 0.001). The RCS models revealed a non-linear relationship between TTR levels and maternal comorbidities, including anemia (adjusted OR 0.992 [95% CI 0.990-0.994]; P = 0.017), liver disease (adjusted OR 0.991 [95% CI 0.988-0.994]; P < 0.001), hypothyroidism (adjusted OR 0.999 [95% CI 0.996-1.001]; P = 0.023) and preterm delivery (adjusted OR 0.986 [95% CI 0.983-0.989]; P < 0.001). The LOESS curves indicated a declining trend in TTR concentrations during the third trimester of pregnancy.
conclusionMaternal TTR concentrations showed an inverse linear association with the incidence of GDM and PE. Moreover, complex non-linear relationships were identified with TTR levels and comorbidities such as liver disease, anemia, hypothyroidism during pregnancy, and preterm delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.